Compare Ginkgo Bioworks Holdings Inc (DNA) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Zscaler Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.98 (market cap $590.53M), while Zscaler Inc trades at $148.47 (market cap $24.59B). The key difference: Zscaler Inc is far larger — about 41.6× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| DNA | ZS | |
|---|---|---|
Market Cap | $590.53M | $24.59B |
Sector | Health | Technology |
52-Week High | $16.14 | $336.27 |
52-Week Low | $5.48 | $118.05 |
Enterprise Value | $627.78M | $22.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Zscaler trades at $141.82, up 1.83% with bearish technical signals despite recent earnings beats. Revenue growth remains strong at $2.67B for 2025, though the company continues to report net losses. Analyst consensus is overwhelmingly bullish with a $192.64 price target, but multiple class action investigations and high valuation metrics create headwinds.
The stock faces near-term pressure from technical weakness and profitability challenges, but long-term prospects remain supported by cybersecurity demand and Zero Trust adoption. Key risks include ongoing litigation, AI infrastructure costs, and the transition to profitability amid slowing growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
